ABSTRACT
Chronic myeloid leukemia (CML) with e6a2 transcript type is very rare in clinic,which is usually related to disease aggressiveness. Its clinical characteristics and relationship with tyrosine kinase inhibitor efficacy are still unclear. In this paper, the clinical characteristics and related laboratory tests of a patient with e6a2 fusion gene positive CML characterized by multiple osteolytic bone destruction throughout the body and eosinophil infiltration in gastrointestinal tract, lymph nodes and other organs were retrospectively analyzed, and the relevant literature was reviewed. The patient was Ph chromosome positive with chromosome +8, and the common BCR::ABL1 transcript of CML was negative, but e6a2 transcript was positive detected by RT-PCR. The patient was treated with dasatinib 100 mg/d. Three months later, the patients achieved CHR, CCyR and MR4.0. However, the e6a2 transcript is very rare in clinical practice, and more cases of e6a2 transcript need to be studied to clarify its clinical characteristics and improve the treatment effect of these rare cases.
Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Male , Oncogene Proteins, Fusion/geneticsABSTRACT
Newborn larva (NBL) antigens of Trichinella spiralis were analysed by Immunoblot, and were compared with the adult and muscle larva antigens. The SDS-PAGE patterns of NBL somatic constituents consisted of about 40 polypeptide bands, which were obviously different from those of adult and muscle larva. Immunoblot analysis indicated that immunization with NBL could induce a stage specific immune response. The molecular weight of specific NBL antigens were 129, 120, 89, 87, 79, 74, 72, 64, 58, 43, 40, 38, 34, 32, and 20kDa. But during the natural course of the infection, we could not detect the antibodies of anti-NBL in the host.